CONNECTA Therapeutics Initiates Phase IIa Study of CTH120
BARCELONA, Spain, June 10, 2026 CONNECTA Therapeutics announced the initiation of a Phase IIa clinical trial evaluating CTH120, its...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
BARCELONA, Spain, June 10, 2026 CONNECTA Therapeutics announced the initiation of a Phase IIa clinical trial evaluating CTH120, its...
COPENHAGEN, Denmark, June 5, 2026 Zealand Pharma announced new results from its Phase 2 ZUPREME-1 clinical trial evaluating petrelintide,...
CHÂTILLON, France and WARREN, N.J., June 2026 DBV Technologies announced that the first participant has been screened in the...
CAMBRIDGE, Mass., June 1, 2026 Fulcrum Therapeutics announced the discontinuation of its lead investigational therapy pociredir for the treatment...
PARIS, France, June 1, 2026 Abivax announced positive topline results from its pivotal Phase 3 ABTECT maintenance trial evaluating...
SUZHOU, China, June 1, 2026 CStone Pharmaceuticals announced updated clinical data for CS2009, its investigational PD-1/VEGF/CTLA-4 trispecific antibody, at...
INCHEON, South Korea, May 29, 2026 Samsung Bioepis Co., Ltd. has announced the European launch of OPUVIZâ„¢ (aflibercept) 40...
DUBLIN, Ireland, May 27, 2026 Jazz Pharmaceuticals has announced the publication of pivotal Phase 3 HERIZON-GEA-01 trial results in...
HERZLIYA, Israel and CALGARY, Alberta, May 27, 2026 Innocan Pharma Corporation has reported strong first-quarter 2026 financial results, highlighting...
SOUTH SAN FRANCISCO, California, May 27, 2026 Human Longevity, Inc. (HLI) has announced the creation of Human Life Foundation...
